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ABSTRACT
We present here a full update of the PMut predic-
tor, active since 2005 and with a large acceptance in
the field of predicting Mendelian pathological muta-
tions. PMut internal engine has been renewed, and
converted into a fully featured standalone training
and prediction engine that not only powers PMut
web portal, but that can generate custom predictors
with alternative training sets or validation schemas.
PMut Web portal allows the user to perform pathol-
ogy predictions, to access a complete repository of
pre-calculated predictions, and to generate and vali-
date new predictors. The default predictor performs
with good quality scores (MCC values of 0.61 on 10-
fold cross validation, and 0.42 on a blind test with
SwissVar 2016 mutations). The PMut portal is freely
accessible at http://mmb.irbbarcelona.org/PMut. A
complete help and tutorial is available at http://mmb.
irbbarcelona.org/PMut/help.
INTRODUCTION
Single nucleotide variants (SNVs) are responsible for∼90%
of human variability (1). When mapped on coding regions
(single amino acid variants, SAVs) may affect the function
of the transcribed proteins (2), leading to phenotype varia-
tions, and often to pathology. Last generation sequencing
and genotyping techniques are reporting a large amount
of human genetic variation data (3), fueling initiatives to
derive links between genome alterations and pathologies.
Thus, the HapMap consortium (4) is characterizing com-
mon variation and linkage disequilibrium patterns that can
be related to common diseases (5). The Human Varia-
tion Project (6) collects, curates, and makes accessible in-
formation on genetic variations affecting human health.
The 1000 Genomes Project (www.1000genomes.org) is ex-
pected to produce the most complete catalog of genetic
variations in human population (7). Already in 2005, the
Wellcome Trust Case Control Consortium genotyped ∼14
000 patients for seven common diseases performing one of
the largest Genome-Wide Association Study (GWAS) (8)
to date. As a result of these and other projects the db-
SNP database at the NCBI (9) collects, nowadays, ∼20
million of validated human SNPs. The manually curated
SwissVar database (10) reports on the pathological effect of
∼61 000 missense SNPs, the public version of the HGMD
database (11) includes>78 000missensemutations causing,
or associated with human inherited diseases, plus disease-
associated/functional polymorphisms and ClinVar reports
over 125 000 clinically relevant variants (12). Systematic
sequencing through NGS of cancer patients (projects like
ICGC, www.icgc.org, and TGCA, cancergenome.nih.gov)
expanded the range of mutations in the human genome. For
example, the present public version of ICGC reports ∼520
000 new somatic SAVs.
Despite the amount of data available, the issue of pre-
dicting the functional consequences of SAVs is still open,
and there is a continuous effort in developing more accu-
rate and flexible predictors (13–15). There is no consen-
sus on the type of approach used to obtained predictions.
PMUT (16), one of the oldest and still widely usedmethods,
uses neural networks, as so does for instance SNAP (17);
SIFT (18), Polyphen (19), PROVEAN (20), LRT (21) and
MutationAssessor (22; Hidden Markov Models are used
in PANTHER (23) and FATHMM (24); Random Forests
are used in PON-P2 (25), CHASM (26), CanPredict (27)
and MuD (28); Support Vector Machines in CADD (29),
SNPs&GO (30), SeqProfCod (31), LS-SNP (32), SNPs3D
(33), MetaSVM (34) andMetaLR (34); Naı¨ve Bayes is used
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inMutationTaster (35), and a gradient boosting tree is used
in M-CAP (36). Also predictors giving consensus predic-
tions like Condel (37), are available. All of them use input
features that represent the change in amino acid sequence,
structure and evolutionary properties resulting from the
amino acid replacement.
PMut (16), first released in 2005, predicted the patholog-
ical nature of a given SAV, and also hot-spot positions on
protein sequences. PMut used a neural network-based clas-
sifier trained by a manually curated dataset extracted from
SwissProt (38), and used sequence conservation and pre-
dicted physico-chemical properties as main features. Here,
we present a major update of the PMut predictor and web
portal.Whilemaintaining the philosophy of the original ap-
plication, the backend classification engine has been com-
pletely renewed and automated, taking advantage of the
increase in the amount of data available for training. The
engine powering PMut is provided as a separate software
package (PyMut) that allows users to prepare their own
predictors for specific families of proteins. The new PMut
web site also provides access to a complete data reposi-
tory, including all possible SAVs on human known proteins.
The web portal is available at http://mmb.irbbarcelona.org/
PMut and has already received more than 900 requests be-
tween 1 January 2017 and 1 April 2017.
PMut PREDICTION ENGINE
PMut prediction engine (PyMut) is prepared as a Python
3 module. PyMut is based on the widely used li-
braries NumPy (www.numpy.org) and Scipy (www.scipy.
org), for fast numerical computing, Pandas (data manage-
ment, pandas.pydata.org), Scikit-learn (machine learning,
scikit-learn.org), Matplotlib (matplotlib.org), and Seaborn
(graphical representation, seaborn.pydata.org). PyMut per-
forms all operations regarding calculation of features, selec-
tion of classifiers, validation and results analysis. It is dis-
tributed as a separate software module that can be down-
loaded and installed locally. Specific functions available are:
• Compute protein features and plot their distribution (see
Supplementary Tables S1 and S2 in the Supplementary
Material for a complete list, and details of the proce-
dures).
• Select the most informative features. Selection of features
is performed in an iterative way, following the improve-
ment of MCC obtained in cross-validation. Supplemen-
tary Figure S1 shows a schema of the algorithm used, and
Supplementary Figure S2 a plot of such MCC evolution.
• Train classifiers, evaluate them using several cross-
validation protocols, and obtain their Receiver Operat-
ing Characteristic (ROC) curves (see Supplementary Ta-
ble S4, and SupplementaryFigure S3 for a list of the avail-
able classifiers and its comparative performance).
• Prepare and evaluate a pathology predictor.
• Predict the pathology of mutations.
PyMut module covers all operations required to generate
newpredictors in a fully automatedway (see Supplementary
Table S5 for a detailed list of software functions, and Sup-
plementary Table S6 for a list of software dependencies),
allowing the user to easily explore alternative datasets, clas-
sifiers or collections of features, enabling to fine tune the
predictor to cover not only pathology, but other structural
or functional characteristics of the proteins. As the mod-
ule can be downloaded and run locally, it allows the user to
analyze private data to derive tailored predictors without
uploading it to a server.
PyMut source code is available at https://github.com/
inab/pymut and in the official Python package repository
(https://pypi.python.org/pypi/pymut), and can be down-
loaded from the PMut Web portal, where a tutorial follow-
ing the main functions of PyMut is also available.
PMut2017 PREDICTOR
PMut2017 default predictor was trained using themanually
curated variation database SwissVar (10) (October 2016 re-
lease), which contains 27 203 disease and 38 078 neutral mu-
tations on 12 141 proteins. Two hundred fifteen numerical
features were first computed for each mutation, account-
ing for (i) physical property differences between wild type
and mutated amino acids, (ii) protein interactome informa-
tion and (iii) amino acid conservation. The conservation
features are derived from local searches over UniRef100
and UniRef90 cluster databases (39), using PSI-Blast (40),
and multiple sequence alignments generated using Kalign2
(41). After evaluation of the different machine learning al-
gorithms (Supplementary Table S4 and Supplementary Fig-
ure S3), the chosen predictor is based on a Random For-
est (42) classifier, trained with only 12 selected features (see
Supplementary Table S3). The classifier outputs a predic-
tion score between 0 and 1; mutations scoring from 0 to 0.5
are classified as neutral, and those scoring from 0.5 to 1 are
classified as pathological. To evaluate the confidence degree
of such score, we have analyzed the accuracy of the predic-
tions based on their score (Supplementary Figure S4). It can
be seen that accuracy increases with extreme score values.
The analysis of these results allows us to qualify the predic-
tion with a statistically meaningful reliability score.
PMut predictor has been validated following several ap-
proaches:
1) A traditional 10-fold cross-validation on protein families
with 50% sequence identity exclusion. No sequence in the
testing set shares >50% sequence identity with any pro-
tein in the training set. Figure 1 shows the correspond-
ing ROC curves. Detailed performance metrics are sum-
marized in Table 1. Restriction of the analysis to most
confident predictions lead to a significant increase in the
performance of the prediction. See Supplementary Fig-
ure S4 for a measured confidence of PMut scores.
2) A blind validation using new SwissVar entries. To perform
this analysis, PMut has been trained using the same pro-
tocol, but limited to the data available at the SwissVar
December 2015 release, and tested with SwissVar 2016
entries (3166 new mutations on 762 proteins. 1656 mu-
tations were tagged as pathological and 1510 as neu-
tral). For comparative purposes, we have also performed
a complete series of analyses of the same test-set using
other prediction methods. Table 2 shows the good per-
formance of PMut when applied to the entire test set.
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Figure 1. ROC Curves corresponding to PMut2017 10-fold cross-validation based on protein families. No sequence in the validation set has more than
50% identity with sequences in the training set. Additional curves correspond to the subsets of prediction with 85% and 90% confidence. AUC: area under
the curve, MCC: Matthews Correlation Coefficient.
Table 1. Summary of performance metrics for PMut2017 predictor
Confidence Coverage Accuracy Sensitivity Specificity AUC MCC
All 100 0.82 0.76 0.86 0.81 0.62
>85% a 85.9 0.85 0.75 0.92 0.83 0.69
>90% a 64.9 0.90 0.80 0.95 0.87 0.77
aOnly predictions with scores corresponding to higher confidence levels are considered (see Supplementary Figure S4).
The new engine used in PMut2017 represents a large im-
provement over the original PMut predictor (MCC 0.03
in the blind validation, data not shown). If predictions
are limited to those cases where more reliable scores are
obtained (PMut 85%), MCC value raises to 0.53, what
puts PMut as the most accurate predictor within the test
performed, covering yet >80% of the mutations. This
can be further improved taking only >90% confidence
scores (MCC 0.62), but in this case predictions can be
obtained only in half of the cases. The availability of Py-
Mut module allows for a seamless update of PMut pre-
dictor when new releases of SwissVar become available.
3) A blind validation using ClinVar entries not included in the
training set. ClinVar (12) is an alternative well known
source for disease related variants. ClinVar includes a
much larger set of variants, although only 34 024 can be
directly mapped to the protein sequences used in PMut.
From those, 13 716 were already present in the SwissVar
training set. To further analyze the performance of the
PMut2017 predictor we have analyzed the variants re-
ported in ClinVar that were not used in the training set
(20 308 variants). Results are shown in Table 2. MCC
value (0.49) is slightly better but comparable with those
obtained in the SwissVar 2016 delta release. This behav-
ior further confirms the prediction power of PMut2017.
4) Comparative test on selected genes. Global validation
schemas provide an averaged estimation of the perfor-
mance of a prediction method. Applying the predictor
to specific protein families may result in a degraded per-
formance due to the individual features of such fam-
ilies. We have selected a number of genes to evaluate
PMut2017 performance in comparison with some other
methods. To avoid a statistical bias, genes have been se-
lected in a way that the number of neutral and patholog-
ical mutations were equilibrated and reasonably large.
Results are reported in Table 3. As expected, MCC val-
ues obtained are specific to the analyzed gene and range
widely around the average value obtained in the global
test. Although some of them show a clearly poorer re-
sult, it can be seen that the behavior is consistent with
the other methods assayed, and shows a good predicting
power. These differences additionally support the need
to develop specific predictors for protein families show-
ing non-standard behavior.
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Table 2. Comparative performance of PMut2017 predictor
Method Coverage (%) Accuracy Specificity Sensitivity AUC MCC
SIFT (18) 89.6 0.61 0.33 0.88 0.60 0.25
Polyphen2 (19) 92.1 0.64 0.35 0.91 0.63 0.32
PROVEAN (20) 91.5 0.64 0.41 0.87 0.64 0.31
FATHMM (24) 90.5 0.55 0.45 0.64 0.55 0.09
PON-P2 (25) 42.4 0.72 0.52 0.9 0.71 0.45
CADD (29) 95.0 0.65 0.33 0.94 0.64 0.35
M-CAP (36) 91.5 0.60 0.19 0.95 0.57 0.22
Condel (37) 91.0 0.63 0.40 0.84 0.62 0.26
LRT (21)a 95.1 0.73 0.58 0.87 0.73 0.47
MutationAssessor (22) a 95.1 0.63 0.46 0.78 0.62 0.26
MetaSVM (34) a 95.1 0.63 0.51 0.74 0.62 0.26
MetaLR (34) a 95.1 0.6 0.46 0.73 0.60 0.20
MutationTaster (35) a 95.1 0.65 0.31 0.96 0.64 0.36
PMut 100.0 0.71 0.65 0.76 0.71 0.42
PMut (85%)b 81.0 0.76 0.76 0.77 0.76 0.53
PMut (90%)b 51.2 0.81 0.78 0.84 0.81 0.62
PMut (ClinVar)c 100.0 0.73 0.88 0.85 0.75 0.49
Blind validation based on new variants added to SwissVar during 2016 (3166 variants), CADD predictor has been evaluated using a threshold of 20. AUC:
area under the ROC curve, MCC: Matthews correlation coefficient.
aAnalysis performed from ANNOVAR data (42).
bAnalysis restricted to most reliable PMut predictions (reliability level in parentheses).
cBlind validation based on variants reported on ClinVar (43), not present in the SwissVar dataset (20,308 variants). Indicated coverage is calculated on
ClinVar dataset.
Table 3. Comparative performance of the PMut2017 predictor on selected genes
Gene Disease #D #N PMut SIFT Polyphen LRT
Mut.
Taster
Mut.
Assessor PROVEAN
MECP2 Rett syndrome 46 22 0.86 0.66 0.85 0.69 0.64 0.41 0.53
COL1A2 Osteogenesis Imperfecta 78 20 0.77 0.74 0.62 0.55 0.55 0.74 0.74
SLC4A1 Distal Renal Tubular Acidosis 38 36 0.69 0.65 0.65 0.54 0.55 0.68 0.60
ADAMTS13 Upshaw-Schulman syndrome 43 17 0.62 0.76 0.46 0.00 0.71 0.54 0.62
ATM Hereditary
cancer-predisposing syndrome
46 54 0.60 0.53 0.57 0.32 0.42 0.48 0.55
ATP7B Wilson disease 195 25 0.48 0.34 0.49 0.37 0.43 0.29 0.52
MLH1+MSH2+MS
H6+PMS2
Lynch syndrome 159 78 0.48 0.32 0.31 0.23 0.16 0.43 0.32
MYOC Primary open angle glaucoma 57 24 0.47 0.37 0.45 0.38 0.50 0.47 0.49
TTC21B Jeune thoracic dystrophy 16 28 0.42 0.20 0.22 0.18 0.16 0.28 0.26
SCN5A Brugada syndrome 154 46 0.40 0.32 0.26 0.43 0.31 0.34 0.34
KCNH2+SCN5A Congenital long QT syndrome 270 54 0.38 0.32 0.28 0.36 0.32 0.30 0.38
ABCA1 Tangier disease 32 31 0.37 0.43 0.31 0.32 0.47 0.43 0.47
PKHD1+PKD1 Polycystic kidney disease 197 96 0.37 0.43 0.37 0.30 0.41 0.36 0.45
FBN1 Marfan syndrome 385 20 0.35 0.31 0.25 0.21 0.33 0.32 0.30
RYR1 Central core disease 147 25 0.34 0.27 0.31 0.00 0.36 0.28 0.34
LDLR Familial hypercholesterolemia 103 23 0.32 0.29 0.08 0.17 0.09 0.26 0.25
DYSF Limb-Girdle Muscular
Dystrophy
48 16 0.31 0.35 0.27 0.15 0.21 0.41 0.39
BRCA2 Breast-ovarian cancer,
familial 2
43 61 0.31 0.10 0.18 0.18 0.14 0.19 0.01
BRCA1 Breast-ovarian cancer,
familial 1
27 36 0.31 0.24 0.20 0.38 0.29 0.30 0.17
WFS1 WFS1-Related Spectrum
Disorders
40 17 0.30 0.25 0.35 0.20 0.18 0.16 0.26
PINK1 Parkinson Disease 23 39 0.25 0.33 0.48 0.40 0.41 0.44 0.30
LRRK2 Parkinson Disease 21 24 0.19 0.06 0.14 0.01 0.13 0.09 0.14
CFTR Cystic fibrosis 146 32 0.15 0.06 0.20 0.21 0.12 0.20 0.27
PROC Thrombophilia 36 28 0.12 -0.15 -0.08 0.07 0.14 0.08 -0.01
MCC values obtained restraining the analysis to variants on the indicated genes. Analysis for non-PMut methods performed fromANNOVAR data (42). #NNeutral mutations,
#D Disease causing mutations.
PMut WEB PORTAL
The access to PMut is possible through a Web por-
tal (http://mmb.irbbarcelona.org/PMut/) which is imple-
mented in Python using the Django Web framework (www.
djangoproject.com). The variants’ features and predictions
are stored in a MongoDB database (www.mongodb.com).
All calculations are performed under the control of a
SGE queuing system configured to deploy additional back-
end workers on peaks of demand. Id mapping and key-
word searches are performed using the appropriate services
at EBI (www.ebi.ac.uk). Sequences, features, variants and
3D structures are obtained from MMB-IRB data repos-
itory (mmb.irbbarcelona.org/api). Most functionalities of
the portal are available anonymously, but the users may reg-
ister to keep records of the activity in the server. After regis-
tering, a private workspace is created with links to the pre-
diction requests, and to their customly trained predictors.
The portal is divided in four sections:
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Figure 2. Partial screenshots of output of Predictor’s training section. (A) Comparative plot of the selected protein features. (B) ROCs curves of performance
evaluation.
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Table 4. Statistics of PMut repository (January 2017)
Proteins available (from human UniRef) 106 407
Analysed variants 725 596 928
Analysed variants (>85% prediction reliability) 586 383 428 (80%)
Analysed variants (>90% prediction reliability) 370 444 279 (51%)
Data repository, which allows the user to access the set of
pre-calculated PMut2017 predictions covering all human
protein sequences in UniRef100. Search options avail-
able include protein name and id (UniprotKB (44) or
PDB (45)), gene id (Ensembl (46)), dbSNP id (9) and free
keywords. Data in the repository can be accessed pro-
grammatically through a REST API. The repository is
continuously updated with new information appearing in
UniRef100 (39). Detailed statistics of the repository can
be found in Table 4.
Pathology prediction, which allows the user to evaluate the
pathological profile of SAVs, input options include pro-
tein id(s), or uploaded sequences. PMut Data Repository
is used to speed up analysis in the case of known pro-
tein sequences. The default predictor is PMut2017, but
Custom Predictors can also be used. In the case of mu-
tations mapping on known sequences all possible single
SAVs are precomputed. The output includes a variety of
graphical and numerical results which are presented in dif-
ferent formats. In all cases, the output combines the in-
formation with known variants and sequence features of
the protein, giving a comprehensive context of the muta-
tions. When 3D structure is available, the mutations are
also mapped onto the structure, using a JsMol visual-
izer (www.jmol.com). Several public databases (Unipro-
tKB (44), PDB (45), PFam (47), InterPro (48) and Inter-
actome3D (49)) are linked to the results card. All inter-
mediate data including alignments and calculated features,
are available for download in the appropriate formats. See
representative screenshots at Help pages on PMut portal,
http://mmb.irbbarcelona.org/PMut/help).
Batch predictions, users requesting larger series of predic-
tions can send them in a single batch. The options avail-
able, and output are equivalent to single requests. The user
is informedwhen thework is finished and results are stored
in his/her private workspace.
Train you own predictor, this section provides a frontend to
the PyMut engine. Users can specify a training set, select a
classifier and a validation procedure. Figure 2 shows some
screenshots of the output. Available information includes
the original training set, a graphical view of the calculated
features (Figure 2A), and a summary of the evaluation re-
sults (Figure 2B). The newly trained predictor becomes au-
tomatically available in the prediction section of the por-
tal. Please note that the use of trained predictors requires
to log in the personal workspace and is restricted to the
user developing it.
CONCLUSIONS
The 2017 new release of the PMut portal constitutes a novel
approach that largely improves our previous 2005 PMut
server. The new portal offers not only a generally trained
predictor that performs in a competitive manner with cur-
rent available methods, but allows the user to access an
automatic procedure to train new predictors with specific
datasets or features. The possibility of enriching the analysis
with alternative predictors, or training predictors with spe-
cific information of a single protein family, largely increases
the scope of usability of the portal. Overall, the 2017 release
of PMut is a powerful tool to approach the issue of predict-
ing functional consequences of protein sequence variants,
and will surely contribute to improve the quality of the an-
notation of pathological variants. The server and platform
are already available and accessible without restrictions.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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